AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26939316
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of acupoint application of jieyu plaster and acupuncture
Trial: 19749461
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (exact dosage not specified)
Trial: 10363732
Drug: Arthrotec 75
RxNorm normalized name: Arthrotec 75 Delayed-Release Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arthrotec 75 (diclofenac sodium 75 mg-misoprostol 200 microg) administered twice daily
Trial: 10363732
Drug: nabumetone 1500
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nabumetone 1500 mg administered once daily
Trial: 1952710
Drug: Tixocortol-neomycin combination
RxNorm normalized name: TIXOCORTOL
DrugBank: Tixocortol (DB09091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixocortol-neomycin combination (Pivalone-Neomycin nasal suspension)
Trial: 1952710
Drug: Placebo (vehicle:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle: N‐cetylpyridinium chloride, sodium chloride, sodium hydroxide solution, benzyl alcohol, purified water, monosodium phosphate)
Trial: 30888584
Drug: Cholecalciferol (4800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (4800 IU/daily)
Trial: 26742487
Drug: Alternative immunosuppressive
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative immunosuppressive scheme (reduced cyclosporine dosage and substituted azathioprine for mycophenolate mofetil) in group 2
Trial: 26742487
Drug: Initial immunosuppressive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial immunosuppressive scheme (azathioprine, cyclosporine, and steroids) in group 1
Trial: 23681940
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) 10–20 mg/kg/day
Trial: 18415773
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate 2 mL (Hyalgan 10.3 mg/mL)
Trial: 18415773
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline 20 mL (distention)
Trial: 18415773
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline 2 mL (placebo)
Trial: 15778423
Drug: Ranolazine in
RxNorm normalized name: Product containing ranolazine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine in combination with diltiazem or simvastatin
Trial: 7540705
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg beta-sitosterol three times per day
Trial: 1781562
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg CD p.o. on the evening before the operation, followed by 25 mg p.o. in the morning
Trial: 1781562
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg F p.o. on the evening before the operation, followed by 1 mg p.o. in the morning
Trial: 7004995
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no corticosteroid therapy)
Trial: 27117175
Drug: Study Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Group (SG, circulating the prime with 40 g albumin for 5 minutes before CPB)
Trial: 27117175
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG, receiving 40 g human albumin 5 minutes after the initiation of CPB)
Trial: 24976416
Drug: Skimmed milk
RxNorm normalized name: Calcium fortified skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skimmed milk (500 mL/d) for 1 year
Trial: 24976416
Drug: Semi-skimmed milk
RxNorm normalized name: Calcium fortified semi-skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-skimmed milk (500 mL/d) for 1 year
Trial: 19770669
Drug: Simvastatin/ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/ezetimibe (10 mg simvastatin and 10 mg ezetimibe, once a day)
Trial: 19770669
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg, once a day)
Trial: 12119507
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (PSL) >12.5 mg/day for at least 1 year
Trial: 12119507
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (BDP) alone
Trial: 4061902
Drug: Intravenous lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine, 1.5 mg/kg
Trial: 16464208
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel (Regranex) plus good wound care (GWC)
Trial: 7956719
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg single dose or 250 mg twice daily)
Trial: 7956719
Drug: Midecamycin acetate
RxNorm normalized name: Midecamycin acetate
DrugBank: Midecamycin (DB13456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midecamycin acetate (600 mg b.i.d.)
Trial: 29843203
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection group (Group S, n = 63)
Trial: 24307656
Drug: High-dose intragraft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intragraft adenosine infusion (200 μg/min; total dose = 2,000 μg)
Trial: 18490173
Drug: Fast track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast track treatment regimen (preoperative fasting 2h, patient controlled epidural analgesia)
Trial: 18490173
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment regimen (preoperative fasting 6h, patient controlled analgesia)
Trial: 18490173
Drug: Fast track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast track treatment regimen
Trial: 18490173
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment regimen
Trial: 8967601
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg midazolam p.o. (Dormicum)
Trial: 6379784
Drug: Non-specific immunotherapy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific immunotherapy (aqueous suspension of heat killed mycobacterium smegmatis, administered subcutaneously once a month)
Trial: 6379784
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no other treatment following excision)
Trial: 29965991
Drug: Ultrasound-guided peripheral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided peripheral nerve block (PNB) with 10 mL prilocaine 1% and 10 mL ropivacaine 0.2%
Trial: 26902832
Drug: Yukmijihwang-tang (YMJ)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yukmijihwang-tang (YMJ) administered at 3g, three times per day for 8 weeks
Trial: 26902832
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 3g, three times per day for 8 weeks
Trial: 25158865
Drug: DPP4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor (sitagliptin 200 mg by mouth)
Trial: 17216336
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg CS‐706 once daily
Trial: 17216336
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg CS‐706 once daily
Trial: 7793169
Drug: Gemeprost (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost (1 mg) as a vaginal suppository in 12 hour intervals
Trial: 7793169
Drug: Dinoprost (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprost (500 micrograms) in a tylose-gel in 6-8 hour intervals
Trial: 2193840
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium
Trial: 842487
Drug: Urea supplementation
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea supplementation (4 g of nitrogen)
Trial: 842487
Drug: Opaque-2 corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaque-2 corn (6 g of nitrogen)
Trial: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation 5 μg/d
Trial: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation 10 μg/d
Trial: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation 6.3 μg/d
Trial: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) supplementation 0 μg/d (placebo)
Trial: 19011511
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposome infusion (VSLI) at 2.0 mg/m infused over 1 hour every 2 weeks (one cycle)
Trial: 19011511
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposome infusion (VSLI)
Trial: 9020419
Drug: 0.5% morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% morphine HCl nasal challenge
Trial: 9020419
Drug: Workplace trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workplace trial with bronchodilator and placebo
Trial: 9020419
Drug: Nasal and
RxNorm normalized name: Nasal and Sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal and bronchial challenge with 0.5% morphine HCl
Trial: 1411923
Drug: Cis platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis platinum (Cis PII) 100 mg/m2 i.v. followed by 6 Gy irradiation in two fractions on days 3 and 5, five cycles at 21 days interval.
Trial: 3871251
Drug: Triple sulfonamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple sulfonamide combined with either phenoxymethyl penicillin or benzathine and procaine penicillin G (IM)
Trial: 20953168
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL lidocaine plus dummy lingual injection (LB)
Trial: 20953168
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL lidocaine (LBL)
Trial: 20953168
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL articaine plus dummy lingual injection (AB)
Trial: 20953168
Drug: 0.9 mL
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mL articaine (ABL)
Trial: 17437743
Drug: Anemia in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia in subjects with CKD (baseline GFR ≤60 ml/min/1.73 m²)
Trial: 12225796
Drug: PEG‐rHuMGDF (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF (various doses)
Trial: 12225796
Drug: PEG‐rHuMGDF (minimally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐rHuMGDF (minimally effective dose)
Trial: 12179676
Drug: Oxytocin administered
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered at the end of the second stage of labor
Trial: 7784413
Drug: Cabergoline (CAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB 0.5‐1 mg twice weekly)
Trial: 7784413
Drug: Bromocriptine (BRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BRC 2.5‐5 mg twice daily)
Trial: 2353171
Drug: Delayed-release, enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release, enteric-coated tablet of mesalazine (Claversal)
Trial: 25906561
Drug: Acupuncture (resuscitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (resuscitation and tranquilization technique) applied to specific acupuncture points (Shenting, Shuigou, Sishencong, Baihui, Feng-chi) once daily, 6 times a week for 8 weeks.
Trial: 25906561
Drug: Deanxit (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deanxit (oral administration, 1 tablet in the morning and lunchtime each day for 8 weeks).
Trial: 380610
Drug: Meptazinol 100
RxNorm normalized name: meptazinol 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 100 mg/70 kg
Trial: 380610
Drug: Pentazocine 60
RxNorm normalized name: pentazocine 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 60 mg/70 kg
Trial: 30961631
Drug: Non-surgical weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical weight loss therapy (hypocaloric diet -500 kcal/day)
Trial: 29389246
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide (Az; 10 mg/kg) plus intravenous dobutamine (Dob) infusion (2-5 μg·kg-1·min-1)
Trial: 29389246
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (Indo; 100 mg)
Trial: 27113231
Drug: Internet-delivered exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered exposure-based cognitive behaviour therapy (ICBT) for 12 weeks
Trial: 24662777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ezetimibe and simvastatin (n = 24)
Trial: 20803425
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day fish oil capsule (with 180 mg EPA and 120 mg DHA, totaling 300 mg n-3 fatty acids)
Trial: 12610804
Drug: Intermittent cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclical etidronate therapy (ICET)
Trial: 10333100
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with three different treatment parameters
Trial: 373071
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive tablets)
Trial: 26051575
Drug: Ginger essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger essential oil inhalation
Trial: 21310101
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate and benzydamine hydrochloride mouth spray (n = 72)
Trial: 16955106
Drug: High-flow treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow treatment (cyclers with high dialysate flow, no manual daytime exchange)
Trial: 16955106
Drug: Manual exchange
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Manual exchange treatment (conventional APD with low nightly dialysate flow and one manual daytime exchange)
Trial: 15727144
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/week for 8 weeks (R1)
Trial: 15727144
Drug: Azithromycin 1500
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1500 mg once upon enrolment (R2)
Trial: 15727144
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (R3)
Trial: 11516807
Drug: tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine 1 mg bd
Trial: 11516807
Drug: tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine 2 mg bd
Trial: 9220215
Drug: Bromfenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac (50 or 100 mg)
Trial: 9220215
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg/oxycodone 10 mg
Trial: 9220215
Drug: Bromfenac (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac (multiple doses)
Trial: 9220215
Drug: Acetaminophen/oxycodone (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/oxycodone (multiple doses)
Trial: 9220215
Drug: Ibuprofen (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (multiple doses)
Trial: 8314271
Drug: sublingual captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual captopril 25 mg
Trial: 31089955
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment as usual
Trial: 27412395
Drug: Electron beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electron beam therapy boost (20 Gy in 10 fractions over 2 weeks)
Trial: 26175290
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health intervention (3 sessions, booklet, mobile phone text-message reminders)
Trial: 24260872
Drug: No postural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postural restrictions after treatment
Trial: 18645164
Drug: IGIV-C 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C 10% at 0.2 g/kg
Trial: 18645164
Drug: IGIV-C 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C 10% at 0.4 g/kg
Trial: 18645164
Drug: IGIV-C 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C 10% at 0.2 g/kg and 0.4 g/kg
Trial: 17073201
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ozone treatment)
Trial: 23696155
Drug: Payment card
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Payment card format (monthly and yearly variants)
Trial: 22231607
Drug: Statin medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin medication use
Trial: 22231607
Drug: Statin medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin medication use (multivariate-adjusted)
Trial: 18235048
Drug: Baseline fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline fasting plasma glucose (FPG) >5 mmol/l
Trial: 16192543
Drug: Stimulating catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulating catheter (Group S); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Trial: 16192543
Drug: Conventional nonstimulating
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional nonstimulating catheter (Group C); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Trial: 12569298
Drug: Capecitabine (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (2500 mg/m2/day for 14 days every 21 days)
Trial: 3075474
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of CsA, azathioprine (AZA), and corticosteroids
Trial: 3075474
Drug: Prophylactic combination
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic combination of CsA, corticosteroids, and antilymphocyte globulins (ALG)
Trial: 3075474
Drug: CsA dose
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA dose lower than or equal to 5 mg/kg per day
Trial: 24948653
Drug: Daily pasture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pasture DM allowance of 3.5% of BW (LO)
Trial: 24948653
Drug: Daily pasture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pasture DM allowance of 7.0% of BW (HI)
Trial: 23540073
Drug: Topical preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical preparations (novel formulations)
Trial: 23540073
Drug: Standard (comparator)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (comparator) formulation